Radioactive antibody targets stubborn MDS cells in early trial
NCT ID NCT06888323
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This early-phase trial is testing a new drug called lintuzumab-Ac225 for people with a type of blood cancer called myelodysplastic syndrome (MDS) that hasn't responded to standard treatments. The drug is an antibody that seeks out cancer cells and delivers a small dose of radiation directly to them. The study will enroll 30 participants to find the safest dose and see if it can shrink or control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber - Harvard Cancer Center LAO
Boston, Massachusetts, 02115, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lintuzumab-Ac225 (a monoclonal antibody linked to a radioactive particle)
What this could lead to
If it works, this could point toward a new treatment option for patients with high-risk MDS that hasn't responded to standard therapy.
What could go wrong
This is a very early (Phase 1) trial with only 30 participants, so it's primarily testing safety and dosing. It may not prove effective, and the radioactive component carries risks like bone marrow suppression.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.